3M Board Declares Quarterly Dividend

Rhea-AI Summary

3M (MMM) declares a dividend of $1.51 per share for the first quarter of 2024, payable on March 12, 2024. The company has a history of uninterrupted dividend payments for over 100 years, driven by a resilient business model. The spin-off of its Health Care business is expected to be completed by the first half of 2024, creating two separate public companies with tailored growth plans and capital allocation strategies.

Financial Analyst

The announcement of 3M's dividend for the first quarter of 2024 is a strong signal of the company's financial health and its commitment to returning value to shareholders. A consistent dividend payout, especially one that has been maintained for over a century, is indicative of 3M's stable cash flow and resilient business model. This kind of financial stability often attracts income-focused investors who are looking for reliable dividend-yielding stocks.

Moreover, the progress on the spin-off of 3M's Health Care business is a critical strategic move that may have significant implications for the company's financial structure and future growth trajectory. The separation into two public entities is likely to provide each with the autonomy to optimize their operational and financial strategies, which could lead to enhanced focus and performance in their respective markets.

Market Research Analyst

The spin-off of 3M's Health Care business is a notable event that reflects a broader trend in the market where conglomerates are simplifying their business structures to unlock shareholder value. By creating two independent companies, 3M is aiming to provide investors with clearer investment propositions and potentially improve capital efficiency. Market analysts will be closely monitoring the performance of both entities post-spin-off to assess the effectiveness of this strategic decision.

Investors should also consider the potential market reactions to such corporate restructuring. If executed well, spin-offs can lead to a re-rating of the companies' stock as the market gains clarity on the separate financials and growth prospects. However, there are also risks involved, including the costs of the transaction and the challenge of establishing strong, independent management teams for both entities.

Legal Expert

The completion of the spin-off is contingent upon various customary conditions, including regulatory approvals. This process can be complex and time-consuming, as it involves scrutiny from regulatory bodies to ensure that the transaction complies with laws and regulations. The legal intricacies of such a corporate restructuring are significant, as they involve considerations related to tax, antitrust laws and the governance structures of the newly formed entities.

For shareholders, it is important to understand that while the spin-off is intended to create value, it is subject to legal and regulatory risks that could affect the timeline and final structure of the transaction. Close attention to the company's disclosures regarding the spin-off process can provide insights into potential legal hurdles and their implications for the expected benefits of the restructuring.

ST. PAUL, Minn., Feb. 6, 2024 /PRNewswire/ -- The 3M Board of Directors (NYSE:MMM) today declared a dividend on the company's common stock of $1.51 per share for the first quarter of 2024. The dividend is payable March 12, 2024, to shareholders of record at the close of business on Feb. 16, 2024.

3M has paid dividends to its shareholders without interruption for more than 100 years driven by its resilient business model. The first quarter dividend reflects the company's continued strong cash flow generation in 2023.

The company continues to make good progress on the spin-off of its Health Care business. The transaction is expected to be completed by the first half of 2024 and is subject to satisfaction of customary conditions, including final approval from the 3M Board of Directors and receipt of regulatory approvals. The completion of the spin will enable the creation of two world-class public companies well positioned to pursue their respective growth plans, tailor capital allocation strategies, and create long-term value for shareholders.

As of Dec. 31, 2023, 3M had 552,581,136 common shares outstanding and 59,969 shareholders of record.

Forward-Looking Statements

This news release contains forward-looking information about 3M's financial results and estimates and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words such as "plan," "expect," "aim," "believe," "project," "target," "anticipate," "intend," "estimate," "will," "should," "could," "would," "forecast" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, regulatory, international trade, geopolitical, capital markets and other external conditions and other factors beyond the Company's control, including inflation, recession, military conflicts, natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) foreign currency exchange rates and fluctuations in those rates; (3) risks related to certain fluorochemicals, including liabilities related to claims, lawsuits, and government regulatory proceedings concerning various PFAS-related products and chemistries, as well as risks related to the Company's plans to exit PFAS manufacturing and discontinue use of PFAS across its product portfolio; (4) risks related to the proposed class-action settlement to resolve claims by public water systems in the United States regarding PFAS; (5) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10-K for the year ended Dec. 31, 2022 and any subsequent quarterly reports on Form 10-Q (the "Reports"); (6) competitive conditions and customer preferences; (7) the timing and market acceptance of new product and service offerings; (8) the availability and cost of purchased components, compounds, raw materials and energy due to shortages, increased demand and wages, supply chain interruptions, or natural or other disasters; (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures, and other strategic events resulting from portfolio management actions and other evolving business strategies; (11) operational execution, including the extent to which the Company can realize the benefits of planned productivity improvements, as well as the impact of organizational restructuring activities; (12) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; (13) the Company's credit ratings and its cost of capital; (14) tax-related external conditions, including changes in tax rates, laws or regulations; (15) matters relating to the proposed spin-off of the Company's Health Care business, including whether the transaction will be completed, or if completed, will be on the expected terms; the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated amounts; the ability to satisfy the various closing conditions; potential business disruption; the diversion of management time; the impact of the transaction (or its pendency) on the Company's ability to retain talent; potential impacts on the Company's relationships with its customers, suppliers, employees, regulators and other counterparties; the ability to realize the desired tax treatment (including whether an Internal Revenue Service private letter ruling will be sought or obtained); the risk that any consents or approvals required will not be obtained; risks associated with financings that may be undertaken and indebtedness that may be incurred in connection with the transaction; and (16) matters relating to Combat Arms Earplugs ("CAE"), including those relating to, the August 2023 settlement that is intended to resolve, to the fullest extent possible, all litigation and alleged claims involving the CAE sold or manufactured by the Company's subsidiary Aearo Technologies and certain of its affiliates and/or 3M. Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located in the Reports under "Cautionary Note Concerning Factors That May Affect Future Results" and "Risk Factors" in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Reports). The Company assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

About 3M

3M (NYSE: MMM) believes science helps create a brighter world for everyone. By unlocking the power of people, ideas and science to reimagine what's possible, our global team uniquely addresses the opportunities and challenges of our customers, communities, and planet. Learn how we're working to improve lives and make what's next at 3M.com/news.

Investor Contact:
Bruce Jermeland
651-733-1807
or
Diane Farrow 
612-202-2449
or
Eric Herron
651-233-0043

Media Contact:
Sean Lynch
slynch2@mmm.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/3m-board-declares-quarterly-dividend-302055258.html

SOURCE 3M Company

FAQ

What is the dividend declared by 3M for the first quarter of 2024?

3M declared a dividend of $1.51 per share for the first quarter of 2024.

When is the dividend payable to shareholders?

The dividend is payable on March 12, 2024.

How many common shares did 3M have outstanding as of Dec. 31, 2023?

As of Dec. 31, 2023, 3M had 552,581,136 common shares outstanding.

What is the status of the spin-off of 3M's Health Care business?

The spin-off is expected to be completed by the first half of 2024, subject to customary conditions and regulatory approvals.